Some GLP-1s, like semaglutide and liraglutide are worth considering
most cases occur in people over 60 Family history : Having a first-degree relative with bowel cancer, especially if diagnosed before age 50 Inflammatory bowel disease : Long-standing ulcerative colitis or Crohn's disease Genetic syndromes : Lynch syndrome (hereditary non-polyposis colorectal cancer) and familial adenomatous polyposis (FAP) Lifestyle factors : Diets high in red and processed meat, obesity, physical inactivity, smoking, and excessive alcohol consumption Type 2 diabetes : People with diabetes have a modestly increased risk of colorectal cancer, independent of medication use Prevention strategies recommended by NICE and the NHS include: Participating in the NHS Bowel Cancer Screening Programme : In England, screening is offered to adults aged 60-74, with ongoing expansion to include ages 50-59 In Scotland and Wales, screening starts at age 50 In Northern Ireland, screening is offered from age 60-74 Maintaining a healthy body weight and engaging in regular physical activity Eating a balanced diet rich in fibre, fruits, and vegetables whilst limiting red and processed meats Avoiding smoking and limiting alcohol intake Promptly reporting red flag symptoms to your GP, including persistent changes in bowel habit, rectal bleeding, unexplained weight loss, abdominal pain, or iron-deficiency anaemia It is important to note that there is no official evidence linking GLP-1 receptor agonists like Ozempic to an increased risk of colon cancer
But we also know of instances where another product would be preferable, and were quick to point that out throughout the article
Semaglutide, the active ingredient in Ozempic, influences multiple physiological pathways, including those involved in skin health
M.BalligandJ
COMPREHENSIVE & ONGOING SUPPORT Our expert team of medical professionals works with you because they care about the physical and mental well-being of every patient we see
